Spagnolo, Boutros, Tanda, Queirolo (2019) The adjuvant treatment revolution for high-risk melanoma patients Seminars in cancer biology ()

Abstract

The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives. Copyright © 2019. Published by Elsevier Ltd.

Links

http://www.ncbi.nlm.nih.gov/pubmed/31445219
http://dx.doi.org/10.1016/j.semcancer.2019.08.024

Tools